Noticias de Eulerpool Nxera Pharma Co

Nxera Pharma Co Eulerpool-AFX

Nxera Pharma Co Noticias de Acciones

Nxera Pharma Co es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Nxera Pharma Co.

• 1 de octubre ·

  Yahoo
  Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
• 1 de octubre ·

  Yahoo
  Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
• 24 de septiembre ·

  Yahoo
  Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
• 13 de septiembre ·

  Yahoo
  Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
• 11 de septiembre ·

  Yahoo
  Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
• 2 de septiembre ·

  Yahoo
  Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• 28 de agosto ·

  Yahoo
  Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• 9 de agosto ·

  Yahoo
  Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
• 9 de julio ·

  Yahoo
  Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
• 9 de julio ·

  SeekingAlpha
  Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth